Russell Investments Group’s Trillium Therapeutics Inc. TRIL Stock Holding History

Russell Investments Group’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-23,927	Closed	-$420K	–	3176
2021 Q3	$420K	Buy	23,927 +536	+2%	+$6.26K	﹤0.01%	2536
2021 Q2	$226K	Sell	23,391 -17,953	-43%	-$169K	﹤0.01%	2868
2021 Q1	$442K	Buy	+41,344	New	+$511K	﹤0.01%	2577
2018 Q4	–	Sell	-5,614	Closed	-$33K	–	3078
2018 Q3	$33K	Hold	5,614	–	–	﹤0.01%	2879
2018 Q2	$34K	Buy	+5,614	New	+$35.8K	﹤0.01%	2850

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Russell Investments Group's TRIL Position: Q4 2021 in Review

Russell Investments Group sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 23,927 shares — an estimated $420K sold.

Russell Investments Group first reported a position in TRIL in Q2 2018 and held it in 5 quarters. The position peaked at $442K in Q1 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Russell Investments Group reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Russell Investments Group sold 23,927 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $420K.
Russell Investments Group first reported a position in Trillium Therapeutics Inc. in Q2 2018 and held it in 5 quarters.
Russell Investments Group's Trillium Therapeutics Inc. position peaked at $442K in Q1 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Russell Investments Group's 13F filing for Q4 2021, filed 21 Jan 2022.